logotype
  • Week's top
  • Latest news
  • Unread news
  • Subscribe

Science X Account

Click here to sign in with or

Forget Password?

Not a member? Sign up

Learn more

  • Addiction
  • Alzheimer's disease & dementia
  • Arthritis & Rheumatism
  • Attention deficit disorders
  • Autism spectrum disorders
  • Biomedical technology
  • Cardiology
  • Dentistry
  • Diabetes
  • Diseases, Conditions, Syndromes
  • Endocrinology & Metabolism
  • Gastroenterology
  • Genetics
  • Gerontology & Geriatrics
  • Health
  • Health informatics
  • HIV & AIDS
  • Immunology
  • Inflammatory disorders
  • Medical economics
  • Medical research
  • Medications
  • Neuroscience
  • Obstetrics & gynaecology
  • Oncology & Cancer
  • Ophthalmology
  • Other
  • Overweight & Obesity
  • Parkinson's & Movement disorders
  • Pediatrics
  • Psychology & Psychiatry
  • Radiology & Imaging
  • Sleep disorders
  • Sports medicine & Kinesiology
  • Surgery
  • Vaccination
  • Asthma
  • Breast cancer
  • Cardiovascular disease
  • Chronic obstructive pulmonary disease
  • Colon cancer
  • Coronary artery disease
  • Dementia
  • Depression
  • Heart attack
  • Heart disease
  • High blood pressure
  • Influenza
  • Kidney disease
  • Leukemia
  • Lung cancer
  • Malaria
  • Melanoma
  • Multiple sclerosis
  • Myocardial infarction
  • Ovarian cancer
  • Post traumatic stress disorder
  • Rheumatoid arthritis
  • Schizophrenia
  • Skin cancer
  • Stroke
  • Type 2 diabetes
  • Full List »
  1. Home
  2. Archive
  3. 04/06/2023

Archive: 04/06/2023

The first line of vaccines was highly effective at restricting COVID-19's damage

After more than three years of COVID-19, the World Health Organization (WHO) reports that over 763 million infections, and nearly seven million deaths, have been attributed to SARS-CoV-2.

Jun 4, 2023

0

28

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, ...

Jun 4, 2023

0

61

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...

Jun 4, 2023

0

54

Phys.org

Phys.org

Daily science news on research developments and the latest scientific innovations

Tech Xplore

Tech Xplore

The latest engineering, electronics and technology advances

ScienceX

Science X

The most comprehensive sci-tech news coverage on the web

Newsletters

Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox

Follow us

  • Top
  • Home
  • Search
  • Mobile version
  • Help
  • FAQ
  • About
  • Contact
  • Science X Account
  • Premium Account
  • Newsletter
  • Archive
  • Android app
  • iOS app
  • RSS feeds
  • Push notification
© Medical Xpress 2011 - 2025 powered by Science X Network
Privacy policy Terms of use Medical Disclaimer

E-mail newsletter

Follow us